We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DxGen Corp.

DxGenco is Point-Of-Care (POC) IVD company focused on developing multi-markers for people with diabetes and tuberculo... read more Featured Products: More products

Download Mobile App





Automatic Point-of-Care System Measures COVID-19 Antibodies Along with HbA1c, CRP, U-Albumin within 3 Minutes

By LabMedica International staff writers
Posted on 06 Oct 2020
A new automatic point-of-care system measures COVID-19 antibodies along with HbA1c, glycated albumin, hemoglobin, C-reactive protein and U-Albumin within just three minutes.

DxGen Corp. More...
(Korea) has launched the Epithod AutoDx analyzer and Epithod SARS-CoV-2 qAb antibody test kit, which allows to easily test IgM/IgG antibodies to SARS-CoV-2. The Epithod SARS-CoV-2 qAb is a vitro diagnostic (IVD) test that can detect IgM and IgG antibodies produced after virus infection in human whole blood and serum/plasma. According to DxGen, the Epithod SARS-CoV-2 qAb test kit has a sensitivity and specificity of 97% and 100%, respectively at 95% confidence intervals.

The test kit is a gold nanoparticle-based immunoassay for semi-quantitative determination with the easy-to-use Epithod AutoDx analyzer. Users can put the test kit and specimen on the tray and press a button, after which the analyzer perform the entire test process automatically. A key benefit of the Epithod AutoDx analyzer is that in addition to measuring IgM/IgG antibodies to SARS-CoV-2, it can also measure various underlying diseases test markers such as HbA1c, glycated albumin, hemoglobin, C-reactive protein, U-Albumin, etc. By providing medical professionals with various and valuable diagnostic information, the Epithod system can be effectively used not only for COVID-19 diagnosis tests, but also for complication diagnosis tests and patient prognosis monitoring and treatment in various medical front lines.

"We are currently processing the FDA EUA, and we have plan to quickly add test kits such as D-dimer, COVID-19 Antigen, Influenza A/B, etc.," said Dr. Jinwoo Lee, CEO of DxGen Corp.




Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
New
Portable POCT Blood Gas Analyzer
BD100
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.